What is the recommended treatment for acute pyelonephritis in an otherwise healthy adult?

Treatment of Acute Pyelonephritis in Otherwise Healthy Adults

For outpatient management of uncomplicated acute pyelonephritis in healthy adults, use oral fluoroquinolones (ciprofloxacin 500-750 mg twice daily for 7 days OR levofloxacin 750 mg once daily for 5 days) as first-line therapy, but ONLY if local fluoroquinolone resistance is <10%. 1

Initial Assessment and Risk Stratification

Before initiating treatment, you must determine whether this is uncomplicated or complicated pyelonephritis, as this fundamentally changes management:

Uncomplicated pyelonephritis is limited to:

• Nonpregnant, premenopausal women
• No known urological abnormalities
• No significant comorbidities 1

Complicated pyelonephritis includes patients with:

• Male sex
• Pregnancy
• Diabetes mellitus
• Immunosuppression
• Urinary obstruction or stones
• Recent instrumentation
• Indwelling catheters
• History of ESBL-producing organisms 1

Diagnostic Workup

Always obtain these before starting antibiotics:

• Urinalysis (white cells, red cells, nitrite) 1
• Urine culture with antimicrobial susceptibility testing - mandatory in ALL cases of pyelonephritis 1

Imaging considerations:

• Ultrasound if history of urolithiasis, renal dysfunction, or high urine pH 1
• CT scan or excretory urography if patient remains febrile after 72 hours OR if clinical deterioration occurs 1

Outpatient Oral Treatment (Uncomplicated Cases)

First-line options (choose based on local resistance patterns):

Fluoroquinolones (preferred):

• Ciprofloxacin 500-750 mg twice daily for 7 days 1, 2
• Levofloxacin 750 mg once daily for 5 days 1, 2

Critical caveat: Fluoroquinolones should only be used if local resistance is <10% 1

Oral cephalosporins (alternative):

• Cefpodoxime 200 mg twice daily for 10 days 1
• Ceftibuten 400 mg once daily for 10 days 1

Important: When using oral cephalosporins empirically, give an initial IV dose of a long-acting parenteral antimicrobial (e.g., ceftriaxone 1-2 g) because oral cephalosporins achieve significantly lower blood and urinary concentrations than IV route 1

TMP-SMX (only if susceptibility confirmed):

• 160/800 mg twice daily for 14 days 1

Agents to AVOID for Empiric Treatment

Do NOT use these for pyelonephritis:

• Nitrofurantoin - insufficient efficacy data 1
• Oral fosfomycin - insufficient efficacy data 1
• Pivmecillinam - insufficient efficacy data 1

Inpatient IV Treatment (Hospitalized Patients)

Indications for hospitalization:

• Severe illness/sepsis
• Persistent vomiting (cannot tolerate oral)
• Failed outpatient treatment
• Complicated pyelonephritis
• Extremes of age 3

Initial IV empiric regimens:

Standard options:

• Ciprofloxacin 400 mg IV twice daily 1
• Levofloxacin 750 mg IV once daily 1
• Ceftriaxone 1-2 g IV once daily (higher dose recommended) 1
• Cefepime 1-2 g IV twice daily (higher dose recommended) 1
• Piperacillin/tazobactam 2.5-4.5 g IV three times daily 1
• Gentamicin 5 mg/kg IV once daily (with or without ampicillin) 1
• Amikacin 15 mg/kg IV once daily 1

Reserve carbapenems and novel agents ONLY for:

• Early culture results showing multidrug-resistant organisms 1
• History of ESBL infection or carriage 4

Carbapenem/broad-spectrum options (when indicated):

• Imipenem/cilastatin 0.5 g IV three times daily 1
• Meropenem 1 g IV three times daily 1
• Ceftolozane/tazobactam 1.5 g IV three times daily 1
• Ceftazidime/avibactam 2.5 g IV three times daily 1

Treatment Duration

Based on high-quality RCT evidence:

• Fluoroquinolones: 5-7 days 2
• Dose-optimized β-lactams: 7 days 2

Important nuance: Shorter courses (5-7 days) are equivalent to longer durations for clinical and microbiological success, but are associated with higher recurrence rates within 4-6 weeks 1. This trade-off must be considered based on local policies and patient factors.

Antibiotic Stewardship and De-escalation

Once culture results are available:

• Switch to narrower-spectrum agent based on susceptibilities 4
• Consider de-escalation to amoxicillin in women if susceptible 4
• Consider ciprofloxacin in men if susceptible 4

Choice of agent should be based on:

• Local resistance patterns (critical) 1
• Individual patient risk factors for resistance 5
• Culture and susceptibility results when available

Follow-up and Treatment Failure

Repeat urine culture 1-2 weeks after completion of therapy 3

If patient remains febrile after 72 hours or deteriorates:

• Obtain imaging immediately (CT scan preferred) 1
• Repeat blood and urine cultures 3
• Consider resistant organisms, anatomic abnormalities, or immunosuppression 3
• May require antibiotic change or surgical intervention 3, 6

Critical Pitfalls to Avoid

1. Do not use fluoroquinolones empirically if local resistance >10% - this threshold is evidence-based and critical for treatment success 1

2. Do not use nitrofurantoin, fosfomycin, or pivmecillinam for pyelonephritis - these are cystitis drugs only, with insufficient tissue penetration 1

3. Do not forget the initial IV cephalosporin dose when using oral cephalosporins - oral bioavailability is inadequate for monotherapy 1

4. Do not delay imaging in patients not improving by 72 hours - obstructive pyelonephritis can rapidly progress to urosepsis 1

5. Always obtain cultures before antibiotics - this is non-negotiable in pyelonephritis, unlike simple cystitis 1